Our team presented an Overview of Phase 1a/b Trial of our Lead Compound IOS-1002 at ESMO 2023. We are very happy with the progress that the Clinical Trial is having and we would love to share more exciting news about it soon! Discover more about the Presentation at ESMO 2023 here: https://lnkd.in/erw5j8UV #ESMO2023 #ESMO #ESMODailyReporter #ESMO23 #immunotherapy #cancer #oncology #clinicaltrial
ImmunOs Therapeutics AG’s Post
More Relevant Posts
-
Join us for a comprehensive overview of current and emerging strategies for managing hematologic malignancies at the 2024 Summit on Hematological Cancers. 🗓️ October 11-13, 2024 📍 Nashville, TN REGISTER HERE 🌐 https://lnkd.in/gKBNWZ2f #CME #cancercare #healthcareprofessional #oncologyeducation #BTF #oncology #cancer #healthequitynow
-
-
Outcomes after pCR in RAPIDO trial of rectal cancer summarized by Erman Akkus, MD EORTC - European Organisation for Research and Treatment of Cancer https://lnkd.in/gMw3bCbG #Cancer #CRT #OncoDaily #Oncology #ClinicalTrials #RectalCancer #PCR #CancerResearch
-
-
Top Science - First prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC https://lnkd.in/eRYGPa_s #Cancer #NSCLC #OncoDaily #Oncology #ClinicalTrials #Immunotherapy #CancerResearch
-
-
Cancer misconceptions are widespread and knowledge is power. Find out the truth behind common cancer myths, from survival rates to early detection - together we can spread facts and not fear. 📣 Get informed and spread awareness, read more: https://lnkd.in/eueiK-P #CancerAwareness #MythBusting #BinaytaraFoundation #CME #cancercare #healthcareprofessional #oncologyeducation #BTF #oncology #cancer #healthequity
-
The OS for patients with EGFR-positive non-squamous cancer was not reached (NR; 95% CI, 35.9 months-NR) between 2017 and 2019 (period 2) and 28.4 months (95% CI, 25.8-30.0; P <.001) between 2014 to 2016 (period 1). https://lnkd.in/gBqyt3ze #NSCLC #cancer #oncology
-
Hope you can join the discussion!
Over the last year, trends in oncology have shifted from KRAS, CD47 and TIGIT to a broad set of new approaches. Below are our top 3 picks. inThought Senior Principal Amanda Weyerbacher, PhD and President Ben Weintraub, PhD will be discussing these topics in a road show throughout September. Please reach out with your availability if you’d like to learn more. #oncology #immunotherapy #cancer #PRMT5 #celltherapy #KRAS #TIGIT #CD47 #BTK #BRAF #ASH2023 #ASH23
-
Did you know Gastric Cancer is the 4th most common cause of cancer mortality? Join Dr. John L. Marshall today at 1:00 PM EST as he shares important updates about the current and future management of gastroesophageal junction cancers. 💻Register for today’s sessions at 1:00 PM EST, 12:00 PM CST, 11:00 AM MDT and 10:00 AM PST: https://ow.ly/8YJo50QoL8O 🖱️Additional Dates & Times: https://ow.ly/PTRx50QoL8R #GastricCancer #cancer #oncology #webinar #MedEd #MedLearningGroup
-
-
"Specialist Medical Oncology in Burjeel medical city Abu Dhabi, Doh& DHA &MOH Licence 🇦🇪🇸🇾, ESMO Member, and Collaborator Extraordinaire - Let's Connect on Telegram and DM for Inspiring Partnerships!"
#ESMO #Breastcancer ⏰ Approximately 60% of all HER2- breast cancers are currently defined HER2-low (IHC 1+ or 2+ ISH-). This review describes how to best identify pts with HER2-low breast cancer with respect to sample type, testing methods, scoring and reporting of HER2 status. Full Text in the comment below 🔻 🔻🔻
-
-
Company plans Phase 2 trial in first-recurrence head and neck cancer, in combination with immune checkpoint inhibitor. #immunooncology #cancer #headandneckcancer #clinicaltrials #immunooncology #cancer #headandneckcancer #clinicaltrials https://buff.ly/3SwvSgZ
-
-
Pancreatic cancer is one of the most challenging cancers and therefore, we must learn more about it. Let us make everyone aware of this cancer which is one of the toughest of all. #worldpancreaticcancerday #pancreaticcancerawareness #pancreaticcanceraction #pancreaticawareness #pancreaticcancerresearch #pancreaticinsufficiency #pancreaticcancersurvivor #pancreaticcancer #KIMSCuddles
